<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065194</url>
  </required_header>
  <id_info>
    <org_study_id>2008-007407-86</org_study_id>
    <nct_id>NCT01065194</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure</brief_title>
  <acronym>LevoRep</acronym>
  <official_title>Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure - A Multicenter, Double-blind, Placebo Controlled Prospective Trial With Two Arms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of a pulsed application of Levosimendan
      versus placebo on the composite end-point functional capacity and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND Significant advances have been made in the treatment of congestive heart failure
      (CHF) in the past few years. Neurohumoral therapy with ACE-inhibitors, ß-blockers and
      aldosterone antagonists has been established to significantly reduce morbidity and mortality.
      However, despite the advances of modern therapy advanced CHF remains a syndrome with a poor
      prognosis. Additionally, this syndrome is associated with poor quality of life and leads to
      progressive debiliation and cardial cachexia. Repeat hospitalizations for acute heart failure
      are common among severe CHF patients. Besides the discomfort for the patients hospital
      admissions constitute the lion's share of the health expenditure for the heart failure
      syndrome.

      Inotropic support is provided to patients suffering acute heart failure refractory to
      neurohumoral therapy. This approach is performed according to the AHA/ACC- as well as to ESC
      Guidelines for therapy of CHF. Inotropic therapy is targeted on hemodynamic stabilization,
      improvement of functional status, and reduction of rehospitalization.

      Moreover, in many centres treatment with inotropes such as dobutamine and milrinone are an
      integral part of the applied bridge to transplant concept in severe heart failure patients.
      In fact, continuous or pulsed inotropic support in severe heart failure patients has been
      tested repeatedly in small clinical studies.

      Intermittent ambulatory low dose administration of dobutamine versus conventional therapy did
      not improve functional capacity in the DICE-Trial. By contrast, several case series with
      different dose regimens of dobutamine indicated improvement of functional status.

      TRIAL RATIONALE Based on its pharmacologic profile Levosimendan appears to be promising in
      the treatment of severe chronic heart failure functional NYHA class III/IV to improve quality
      of life and physical activity and to reduce hospital admissions for acute heart failure.

      Repeat drug administration may be superior over a single shot therapy to maintain beneficial
      long-term results.

      For economical reasons and for the sake of the patients comfort drug administration should
      ideally be managed on an outpatient basis rather than in the hospital. Therefore and for
      practical reasons, a time period of six hours for drug administration might be reasonable.

      Dosing of the drug will be based on the experiences in the Russlan Trial and on a small case
      report by Martys. In the latter study serial administration of levosimendan for 6 hours
      (bolus of 12 mcg/kg followed by a continuous infusion of 0,1 μg/kg/min for 50min and 0,2
      μg/kg/min for the next 5 hours) induced a significant fall of BNP.

      In an outpatient setting, however, a bolus should be not be given for safety reasons.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients showing an improvement in the six-minutes walk test and a higher scoring in the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>effects of a pulsed application of levosimendan on event free survival</measure>
    <time_frame>8 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects of a pulsed application of levosimendan on event free survival</measure>
    <time_frame>24 weeks from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Stable Heart Failure</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic stable heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chronic Stable Heart Failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic stable heart failure NYHA III and IV diagnosed at least 3 months
             before inclusion

          -  6-min.-walk-test &lt; 350 meters

          -  EF &lt; 35 %

          -  Age &gt; 20 years

          -  Optimized and individualised neurohormonal background therapy according to
             ESC-guidelines for the treatment of chronic heart failure.

          -  Patient has signed informed consent

        Exclusion Criteria:

          -  Hospitalization for decompensated heart failure requiring i.v. diuretics within the
             last month before randomization

          -  History of torsades des pointes

          -  Allergy to Levosimendan or any of the excipients

          -  Administration of inotropes in the last 4 weeks

          -  Potassium &lt;3,5 and &gt;5,5 mmol/l

          -  Systolic blood pressure &lt;= 100 mmHg

          -  Women at childbearing age without using effective contraceptives ( oral
             contraceptives, intrauterine contraceptive devices) unless surgical sterilisation has
             been undertaken.

          -  Female patients who are pregnant or nursing

          -  Creatinin Clearance &lt; 30ml/min/m2

          -  Severe anemia (Hb &lt; 10 mg /dl)

          -  Mechanical obstruction affecting the ventricular filling or the outflow or both

          -  Patients with non compliance

          -  Severe conditions, which make the patient unsuitable to participate in a study as
             judged by the investigator

          -  Severe liver disease

          -  Percutaneous coronary intervention within the last 1 months

          -  Coronary bypass surgery within the last 3 months

          -  Planned HTX within the next six months

          -  Patient involved in another clinical trial

          -  De-nove heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johann Altenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paracelsus Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johann Altenberger, MD</last_name>
    <phone>+436624482</phone>
    <phone_ext>57560</phone_ext>
    <email>j.altenberger@salk.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerhard Poelzl, MD</last_name>
    <phone>+43512504</phone>
    <phone_ext>81318</phone_ext>
    <email>gerhard.poelzl@uki.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Poelzl, MD</last_name>
      <phone>+43512504</phone>
      <phone_ext>81318</phone_ext>
      <email>gerhard.poelzl@uki.at</email>
    </contact>
    <investigator>
      <last_name>Gerhard Poelzl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allg. öffentliches Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Ebner, MD</last_name>
      <phone>+4373276760</phone>
      <email>christian.ebner@elisabethinen.or.at</email>
    </contact>
    <investigator>
      <last_name>Christian Ebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mori, MD</last_name>
      <phone>+437327677</phone>
      <email>michael.mori@bhs.at</email>
    </contact>
    <investigator>
      <last_name>Peter Siostrzonek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allgemeine Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Sihorsch, MD</last_name>
      <phone>+437327806</phone>
      <phone_ext>6235</phone_ext>
      <email>kurt.sihorsch@akh.linz.at</email>
    </contact>
    <investigator>
      <last_name>Franz Leisch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medical University Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Altenberger, MD</last_name>
      <phone>+436624482</phone>
      <phone_ext>57560</phone_ext>
      <email>j.altenberger@salk.at</email>
    </contact>
    <investigator>
      <last_name>Johann Altenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landesklinikum St. Poelten</name>
      <address>
        <city>St. Poelten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Berger, MD</last_name>
      <phone>+432742300</phone>
      <phone_ext>14706</phone_ext>
      <email>rudolf.berger@stpoelten.lknoe.at</email>
    </contact>
    <investigator>
      <last_name>Rudolf Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiserin Elisabeth Spital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1150</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lida Dimopoulos-Xicki, MD</last_name>
      <phone>+43/198104</phone>
      <phone_ext>2108</phone_ext>
      <email>Lida.Domopoulos-Xicki@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Stefenelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels Grieskirchen</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Weber, MD</last_name>
      <phone>+437242415</phone>
      <phone_ext>2215</phone_ext>
      <email>Thomas.Weber@klinikum-wegr.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>G. Gennimatas General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apostolos Karavidas, MD</last_name>
      <email>akaravid@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Apostolos Karavidas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterini Avgeropoulo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ekaterini Avgeropoulo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Failure Clinic, Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Parissis, MD</last_name>
      <email>jparissis@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>John Parissis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>August 27, 2010</last_update_submitted>
  <last_update_submitted_qc>August 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical University Innsbruck</name_title>
    <organization>Department of Internal Medicine III / Cardiology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

